Newroom
New publication SUL-121 compound
In the range of compounds for protecting organs from Sulfateq a new paper is published. We are proud to announce that Dr. L.E. (Leo) Deelman (UMCG) has published his paper on the protective effects of our SUL-121 compound in diabetes. SUL-121...
Dr. Rob Henning on hibernation (BBC2)
Tonight (11 September 2017) please tune in to BBC2. At 22:00 (Dutch time), Professor Rob Henning of the UMCG discusses the need for human hibernation. In this episode of "The search for a new world" Christophe meets anaesthesiologist Dr. Rob...
Sepsis: a new application for the SUL-compounds?
Sulfateq B.V. is dedicated to developing new drugs for several diseases: Acute Kidney Injury (AKI), Chronic Obstructive Pulmonary Disease (COPD), Type II Diabetes (T2D) and obesity. We can now proudly announce that the SUL-compounds are being...
New publications ROKEPIE
Lately there is a lot of happening at Sulfateq which is very positive for the development of ROKEPIE. Besides our new website there are also multiple publications and papers which have been published or will be published in the near future. What’s...
BIO-Europe 2016 – Cologne
From 7 till 9 November 2016 we will be attending BIO-Europe 2016 in Cologne (Germany). BIO-Europe is Europe's largest partnering conference serving the global biotechnology industry. Our CEO Kees van der Graaf will be present on these days to talk...
The Sulfateq compound SUL-121 is proven to potentially contribute to the treatment of COPD
We are proud to announce that one of our SUL-compounds, SUL-121, is proven to have both an anti-inflammatory and bronchodilating effect in vitro and in vivo. In the study, performed by the University of Groningen, the researchers explored the...